Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
A novel oral formulation of the GLP-1 receptor agonist semaglutide (Rybelsus) was recently approved for the treatment of T2DM
CONCERTO: a randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis
Reports and Surveys | January 22, 2026 We conducted a cost-benefit analysis of glucagon-like peptide-1 agonists (GLP-1s) using data from SHAPE, our proprietary health data warehouse
9(234), 2024 [2] FAQs GLP-1 RA shortages (Accessed January 9, 2025) [3] Primary packaging container considerations for GLP-1-based drugs (Accessed January 10, 2025) [4] Riding the Wegovy wave: The startups shifting focus to GLP-1s to tap the $150bn weight loss drug market (Accessed January 13, 2025) [5] 5 Reasons Why 2025 Is The Year Pharma Companies Will Revisit Their Drug Delivery Device Strategies (Accessed January 13, 2025) [6] UK-based Verdiva launches with $410m and an oral GLP-1RA candidate (Accessed January 13, 2025) [7] Arrick G, Sticker D, Ghazal A et al
At the end of the 80-week trial, the average results showed: Participants on a 4 mg dose lost 29.8 pounds (lb), or about 12.7 percent of their starting body weight
